MuReva Phototherapy has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase II grant by the  National Institutes of Health (NIH) to continue development of the company’s novel phototherapeutic light delivery device which is designed to become the standard of care for the prevention and treatment of oral mucositis. The NIH provided a $1.5 million grant over two years to support the project​ entitled “Non-Invasive Intraoral LED Phototherapy Device for the Prevention and Treatment of Oral Mucositis” (link).

The objective of a SBIR Phase II grant is to provide additional non-dilutive funding to continue the R&D efforts initiated in Phase I. Funding is based on the results achieved in Phase I, scientific/technical merit and commercial potential of the project proposed in Phase II. The original Phase I SBIR grant for MuReva Phototherapies technology was previously awarded to Lumitex, Inc. in 2016 (link). MuReva Phototherapy’s technology was spun out of Lumitex in 2019.